Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna G Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia M Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Maria T Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi
INTRODUCTION: Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of patients with severe AD after being evaluated in several clinical trials. However, a few concerns have been raised regarding their long-term safety and the management of these drugs in real-world clinical practice. In this article we described the results of a Delphi consensus aimed at describing the knowledge on JAKi and focusing, in particular, on providing clinical recommendations for dermatologists in daily practice regarding the use of these drugs...
March 21, 2024: Dermatology and Therapy